Menu

About OIC

OIC and pain control OIC negatively impacts QOL The role of mu-opioid receptors Laxative failure: what’s next?

About MOVENTIG (naloxegol)

Mechanism of action SBM efficacy Safety Prescribing information

OIC Checklist

OIC treatment checklist

MOA, mechanism of action; OIC, opioid-induced constipation; QOL, quality of life; SBM, spontaneous bowel movement.

Moventig Story

When they only share some of their story…

…they can only get part of your help

For the United Kingdom:

Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse Events should also be reported to Kyowa Kirin Ltd. on +44 (0)1896 664000, email medinfo@kyowakirin.com

For the Republic of Ireland:

Adverse Events should be reported. Information about adverse event reporting can be found at www.hpra.ie. Adverse Events should also be reported to Kyowa Kirin Ltd. on +44 (0)1896 664000, email medinfo@kyowakirin.com

Could uncovering what patients are holding back lead to better care?

Discover the whole story arrow icon

KKI/INT/MOV/0107 May 2022

This material is not optimised for mobile operating systems. Please log-in using a desktop device.

This material is not optimised for mobile operating systems. Please log-in using a desktop device.